Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Vanderbilt licenses mGluR4 modulators for Parkinson’s to BMS

Executive Summary

Vanderbilt University’s Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has licensed Bristol-Myers Squibb Co. rights to develop and market its positive allosteric modulators of the metabotropic glutamate receptor 4 (mGluR4) for Parkinson’s disease (PD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register